ClinicalTrials.gg
RecruitingNCT05841472Updated Aug 30, 2023

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

A Phase 2 interventional study of Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin in Non Squamous Non Small Cell Lung Cancer, sponsored by CrystalGenomics, Inc.. Recruiting at 8 sites in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-30.

Sponsored by CrystalGenomics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung — 6 open to participants now, 7 under way, 1 of them phase 3. camrelizumab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
11th of 27
60 · median 58
Started
2023
with 1 other
Phase 2
17 of 27
4 open now
Registered
25th of 27
by date
Lead sponsor
1 of 27
CrystalGenomics, Inc.

Among the 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by planned enrollment, is one of 2 that started in 2023, is one of 17 in phase 2, and was the 25th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The objective of this bridging study is to acquire new drug approval in Korea for camrelizumab (SHR-1210), a drug that has already been approved in China for treatment in patients with histologically or cytologically confirmed advanced or metastatic (Stage IIIB-IV), EGFR/ALK wild-type, non-squamous, non-small cell lung cancer. In this study, subjects with advanced or metastatic, EGFR/ALK wild-type, non-squamous, non-small lung cancer will receive anti-PD-1 antibody therapy of camrelizumab in combination with pemetrexed + carboplatin as first-line treatment for at least 8 cycles (24 weeks). Then, the best overall RECIST responses (BOR) from subjects who have had at least 1 post-baseline tumor assessment will be evaluated to confirm that camrelizumab, a drug that has already been approved China, has similar efficacy in the Korean population as in the Chinese population.

03

Conditions studied

  • Non Squamous Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Subject aged between 19-80 at the time of signing the form, male or female.
  2. or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC), Stage IIIB-IV (as per the International Association for the Study of Lung Cancer (IASLC) Staging Handbook in Thoracic Oncology, 8th Edition).
  3. The site must provide documented information on EGFR mutation and ALK translocation and both must be negative. Subject cannot be randomized before receiving the source document for EGFR mutation and ALK translocation.
  4. A tumor tissue specimen collected upon or after diagnosis of advanced or disease, either fresh or archival (within 6 months prior to the first dose), must be provided. At least 10 unstained slides can be generated from the formalin fixed, paraffin-embedded (FFPE) tumor tissue block for immunohistochemistry assay or biomarker testing (or may be less than 10 slides as approved by the sponsor's medical monitor). Specimen obtained from fine needle aspiration, pleural fluid smear, or drill are unacceptable. For bone lesions, specimen without soft tissue components or decalcified bone tumor specimen is also unacceptable.
  5. Subjects who have not previously received systemic chemotherapy for advanced/metastatic NSCLC. Chemotherapy as /adjuvant therapy or chemoradiotherapy is permitted, as long as the treatment has been completed at least 12 months before the diagnosis of advanced or metastatic disease.
  6. Radiographically via CT or MRI, as per 1.1. The tumor assessment of baseline should be performed within 28 days prior to the first dose.
  7. PS score: 0-1.
  8. Expected survival ≥ 3 months.
  9. Subjects must undergo all screening laboratory tests as per the protocol within 14 days prior to the first dose. Laboratory tests at screening must meet the following criteria:
  1. Hematology: (without blood transfusion, G-CSF, or medication within 14 days prior to screening)
  1. (HB) ≥ 90 g/L;
  2. (ANC) ≥ 1.5 x 109/L;
  3. (PLT) ≥ 100 x 109/L;
  4. White blood cell (WBC) ≥ 4.0 x 109/L and ≤ 15 x 109/L; 2) Biochemistry: (no blood or albumin transfusion within 14 days prior to screening)
  5. and ALT ≤ 1.5 x (≤ 5 x ULN for liver metastasis);
  6. ALP ≤ 2.5 x ULN (≤ 5 x ULN for bone metastasis);
  7. ≤ 1.5 x ULN;
  8. ALB ≥ 30 g/L;
  9. Cr ≤ 1.5 x ULN, and (CrCL) ≥ 60 mL/min (Cockcroft-Gault equation);
  10. ≤ 1.5 x ULN, and INR or PT ≤ 1.5 x ULN (no anticoagulant therapy).

    1. Female subjects of must have a negative serum pregnancy test within 3 days prior to the first dose. Female subjects of childbearing potential and male subjects with partners of childbearing potential must agree to use adequate method of during the study period and 180 days after the last dose of study medication.
    1. Subject has voluntarily agreed to participate by giving written informed consent/assent.

    Exclusion Criteria:

    1. Exclusion criteria for the target indication
    2. Subjects with other histological types besides non-squamous non-small cell lung cancer, including mixed carcinomas or NSCLC with small cell lung cancer components/neuroendocrine differentiation.
    3. Subjects with EGFR mutation or ALK translocation.
    4. Subjects without radiographically measurable lesions.
    5. Subjects with carcinomatous meningitis and spinal cord compression.
    6. Subjects with untreated central nervous system (CNS) metastasis. Subjects with previously treated may participate if the CNS metastasis is limited to the supraentorial and cerebellar regions, adequately treated, and clinically stable (by radiological tumor assessments, preferably enhanced MRI or CT) for at least 4 weeks, and if the subject's neurological symptoms can return to Grade ≤ 1 within 2 weeks prior to the first dose. In addition, subjects who are using for clinical symptoms are not eligible, unless the doses of corticosteroids stable or gradually reduced to prednisone ≤ 10 mg/day (or equivalent) -for at least 2 weeks.
    7. Subjects who can be treated with surgical resection or radical radiotherapy.
    8. Subjects who previously received treatment with any other (L1) or CTLA4 monoclonal antibodies.
    1. Medical history and complications
    2. Subjects with any active, known, or suspected diseases. Subjects who are clinically stable and do not require systemic , such as those with Type I diabetes, hypothyroidism requiring only hormone replacement therapy, or skin diseases that do not require systemic treatment (for example, vitiligo, psoriasis or alopecia), or subjects in whom recurrence are not expected without external triggers may be eligible.
    3. Subjects with any complication that require systemic corticosteroids like prednisone (> 10 mg/day or equivalent) or other immunosuppressants within 14 days prior to the first dose. In the absence of active autoimmune disease, inhaled or topical use of corticosteroids, and physiologic hormone replacement therapy for adrenal insufficiencylike prednisone > 10 mg/day or equivalent are permitted;
    4. Subjects who received cancer vaccines or other immunostimulatory anti-cancer agents (interferon, interleukin, thymosin, or immune cell therapy) within 1 month prior to the first dose.
    5. Subjects who are currently participating and receiving study therapy or has participated in a study of an agent and received study therapy within 4 weeks (or 5 half-lives of the previous investigational agent) prior to the first dose.
    6. Subjects who are expected to require any other forms of anti-cancer treatment (including maintenance treatment with other drugs, radiotherapy, and/or surgical resection) for NSCLC while on study.
    7. Subjects who received major surgery within 4 weeks prior to the first dose, non-thoracic radiation therapy > 30 Gy within 4 weeks prior to the first dose, thoracic radiation therapy > 30 Gy within 24 weeks prior to the first dose, or palliative radiation ≤ 30 Gy within 2 weeks prior to the first dose, and failed to recover from the toxicities and/or complications of these interventions to NCI-CTC AE Grade ≤ 1 (except for alopecia and fatigue). Palliative radiotherapy for symptomatic control is permitted, but must be completed within 2 weeks prior to the first dose and no additional radiotherapy should be scheduled for the same lesion.
    8. Subjects highly suspected of interstitial lung disease, or with conditions that may interfere with the testing or management of suspected treatment-related pulmonary toxicities, or other moderate to severe lung diseases that seriously affect pulmonary function.
    9. Subjects who require concomitant treatment for other active malignant tumors.
    10. Subjects with a history of prior malignant tumors, except for basal cell carcinoma, superficial bladder cancer, squamous cell carcinoma of the skin, or cervical carcinoma in situ with complete remission for at least 5 years prior to screening and no additional treatment is required or expected while on study.
    11. Subjects with Grade II or higher myocardial ischemia or myocardial infarction, or poorly controlled arrhythmias. Subjects with Class III-IV cardiac insufficiency or an (left ventricular ejection fraction) \< 50% by echocardiography.
    12. Subjects with significant hemoptysis or coughing a daily volume up to half a teaspoon (2.5 mL) or more of blood within 1 month prior to randomization.
    13. Subjects with hemorrhage or clear bleeding tendency within 1 month prior to randomization, such as GI bleeding, hemorrhagic gastric ulcer, or vasculitis.
    14. Events of arterial/venous thrombosis within 3 months prior to randomization, such as cerebrovascular accidents (including , cerebral hemorrhage, brain infarction), deep vein thrombosis, and pulmonary embolism.
    15. Subjects with active pulmonary tuberculosis (TB). Active TB should be ruled out in subjects suspected of such condition, by chest X-ray, sputum test, and examinations of clinical symptoms and signs. Subjects with a history of active TB infection within 1 year prior to the screening are excluded, despite being treated. Subjects with a history of active TB infection more than 1 year ago can be enrolled if the course and type of TB treatment are appropriate.
    16. Subjects with serious infection within 4 weeks prior to the first dose, including but not limited to infective complications, bacteremia and severe pneumonia that require hospitalization. Subjects with any active infections are excluded, lymphangitic spread of the NSCLC is not exclusionary.
    17. Subjects who prepare to receive or have previously received tissue/organ transplants.
    18. Subjects who plan to receive or have received within 30 days prior to the first dose.
    19. Subjects with for platinum-based medications before the first dose: gout, varicella, herpes zoster, and Grade ≥ 2 peripheral neuropathy.
    20. It is not recommended to enroll subjects with uncontrolled tumor-related pain. Subjects requiring pain medication must have a stable regimen before randomization. Palliative radiotherapy for symptomatic lesions (such as bone metastasis or perineural invasion) should be completed at least 2 weeks before enrollment. Loco-regional treatment should be considered before randomization, if appropriate, for asymptomatic metastatic lesions where further growth may result in functional deficits or intractable pain (e.g., epidural metastasis without spinal cord compression).
    1. Physical examination and laboratory tests
    2. Subjects have known history of (HIV) seropositive status or acquired immunodeficiency syndrome (AIDS).
    3. Subjects with untreated active hepatitis. : Hepatitis B surface antigen (HBV sAg) positive and HBV DNA greater than the upper limit of normal; : HCV antibody (HCV Ab) positive and HCV RNA positive, and abnormal hepatic function; Hepatitis B and C coinfection.
    4. Subjects with uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
    1. Allergies and adverse drug reactions
    2. Severe allergic, anaphylactic, or other reactions to other monoclonal antibodies.
    3. Allergy or intolerance during an infusion.
    4. History of severe allergies to pemetrexed, carboplatin, or their premedications.
    1. Subjects with mental illness, alcohol abuse, inability to quit smoking, and drug or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
    1. Based on the investigator's opinion, subjects with a history or current evidence of any condition, diseases, treatments, or laboratory abnormalities that may confound the study results, interfere with study procedures, or are not in the best interests of the subjects, should be excluded.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Camrelizumab, Pemetrexed and Carboplatin

    Drug: Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin

Interventions

  • DrugCamrelizumab (SHR-1210), Pemetrexed, and Carboplatin

    Drug page: Camrelizumab

    * 200 mg of Camrelizumab (SHR-1210) is administered intravenously over a period of around 20-60 min on Day 1 of each 3-week cycle. * Pemetrexed 500 mg/m2 is administered intravenously on Day 1 of each 3-week cycle, over a period of more than 10 minutes * Carboplatin of AUC 5 is administered intravenously on Day 1 of each 3-week cycle (hydrated as appropriate), over a period of more than 30 minutes by 4-6 cycles.

06

What researchers measure

Primary outcomes

  1. Best overall RECIST response, BoR

    Time frame: up to 8 cycles (24 weeks) of the last subject

Secondary outcomes

  1. Progression Free Survival (PFS)

    Time frame: 6 months, 12 months, 24 months

  2. Objective response rate (ORR)

    Time frame: 6 months, 12 months, 24 months

  3. Overall survival (OS)

    Time frame: up to 6 months from the last visit of the last patient

  4. Disease control rate (DCR)

    Time frame: 6 months, 12 months, 24 months

07

Study locations

8 of 8 sites recruiting
  • Korea University Anam Hospital
    Anam, Korea, Republic of
    Recruiting
    • Sooin Choi, M.D. · Contact
  • Hallym University Sacred Heart Hospital
    Anyang, Korea, Republic of
    Recruiting
    • Seung Hoon Jang · Contact
  • Chonnam National University Hwasun Hospital
    Hwasun, Korea, Republic of
    Recruiting
    • Injae Oh, M.D. · Contact
  • Catholic University of Korea EunPyeong St. Mary's Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Chang Dong Yeo, M.D. · Contact
  • Catholic University of Korea Yeouido St. Mary's Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Chan Kwon Park, M.D. · Contact
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Sung Yong Lee, M.D. · Contact
  • Seoul Asan Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Chang Min Choi, M.D. · Contact
  • Busan National University Hospital Yangsan
    Yangsan, Korea, Republic of
    Recruiting
    • Sunghoon Yoon, M.D. · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Aug 2026, 36 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 36 months is close to that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2023
First posted
May 3, 2023
StartActual
Aug 23, 2023
Primary completionEst.
Aug 2026
CompletionEst.
Dec 2026
Last update
Aug 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05841472
Lead sponsor
CrystalGenomics, Inc.
Responsible party
Sponsor
First posted
May 3, 2023
Start date
Aug 23, 2023
Primary completion
Aug 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 30, 2023

Study contacts

Kyung Hye Kim
Contact
khkim@cgxinc.com
+821087370206
Sung Yong Lee, MD
principal investigator · Korea University Guro Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion